Last reviewed · How we verify

Baminercept alfa 3 — Competitive Intelligence Brief

Baminercept alfa 3 (Baminercept alfa 3) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrogenic cytokine inhibitor. Area: Fibrosis, Oncology.

phase 2 Fibrogenic cytokine inhibitor TGF-beta superfamily members Fibrosis, Oncology Biologic Live · refreshed every 30 min

Target snapshot

Baminercept alfa 3 (Baminercept alfa 3) — Biogen. Baminercept alfa 3 is a fusion protein that targets and modulates the activity of TGF-beta superfamily members.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Baminercept alfa 3 TARGET Baminercept alfa 3 Biogen phase 2 Fibrogenic cytokine inhibitor TGF-beta superfamily members

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrogenic cytokine inhibitor class)

  1. Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baminercept alfa 3 — Competitive Intelligence Brief. https://druglandscape.com/ci/baminercept-alfa-3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: